ArticleJAMA oncology2024

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.

Yusuke Okuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.